These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 590287)

  • 21. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
    Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C; Fiedler H; Wohlrab W; Wozniak KD
    Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
    Hu F; Woodward WR; Peterson LL
    J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Melanoma metabolites (proceedings)].
    Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4596-7. PubMed ID: 723347
    [No Abstract]   [Full Text] [Related]  

  • 27. 5-S-cysteinyldopa in urine and tumors.
    Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
    J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
    Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
    Nixon PF
    Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
    Jönsson PE; Agrup G; Arnbjörnsson E; Hafström L; Rorsman H
    Cancer; 1980 Jan; 45(2):245-8. PubMed ID: 6153150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G; Hafström L; Jönsson PE; Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
    [No Abstract]   [Full Text] [Related]  

  • 33. Glutathionedopa in malignant melanoma.
    Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1977; 57(3):221-2. PubMed ID: 71825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary excretion of 5-S-cysteinyldopa in healthy Japanese.
    Morishima T; Hanawa S
    Acta Derm Venereol; 1981; 61(2):149-50. PubMed ID: 6165192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-S-cysteinyldopa, dopa, and dopamine in the kidney and some other tissues.
    Agrup G; Hansson C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1980; 60(1):63-4. PubMed ID: 6153836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-S-Cysteinyldopa in ganglion stellatum.
    Fehling C; Hansson C; Poulsen J; Rorsman H; Rosengren E
    J Neural Transm; 1981; 52(3):251-7. PubMed ID: 6796651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
    [No Abstract]   [Full Text] [Related]  

  • 39. A new approach to the differential diagnosis of human malignant melanomas.
    Rougé F; Aubert C
    Cancer; 1979 Jul; 44(1):199-209. PubMed ID: 455245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UVB-induced melanocyte proliferation and 5-S-cysteinyldopa excretion in dysplastic nevus syndrome.
    Stierner U; Augustsson A; Rosdahl I; Kågedal B; Suurküla M
    Photodermatol; 1988 Oct; 5(5):218-23. PubMed ID: 3146749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.